Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Harris

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|June 21, 2001
The Effects of Candesartan Cilexetil in Isolated Systolic Hypertension: A Clinical Experience TrialJoel M. Neutel, Matthew R. Weir, Marvin Moser, et al.
Journal of Drugs in Dermatology : JDD|July 30, 2020
Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/EthnicityNeal Bhatia, Jonathan S Weiss, Neil Sadick, et al.
Rural and Remote Health|December 7, 2023
Exploring barriers and promoters of CRC screening use among agricultural operators: a pilot study of an application of concept mappingCheryl Beseler, Jungyoon Kim, Roma Subramanian, et al.
Postgraduate Medicine|May 14, 2010
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesRobert Frederich, John H Alexander, Fred T Fiedorek, et al.
Journal of the American Academy of Dermatology|September 19, 2018
Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasisMark G Lebwohl, Jeffrey L Sugarman, Linda Stein Gold, et al.
American Journal of Medical Genetics. Part A|July 16, 2008
Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorderCatalina García-Nonell, Eugenia Rigau Ratera, Susan Harris, et al.
Cutis|March 21, 2019
Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studiesJeffrey L Sugarman, Jonathan S Weiss, Emil A Tanghetti, et al.
Journal of Pediatric Hematology/Oncology|September 10, 2002
CD3+CD4-CD8+NK- large granular lymphocytosis with neutropenia and evidence for clonality and T-cell receptor gene rearrangement: two pediatric casesMamidipudi T Krishna, Elizabeth Hodges, Frances L Lavender, et al.
Cancers|November 9, 2024
The Effect of a Tailored Educational Flyer on Colorectal Cancer Screening Among Rural Residents: Lessons Learned from a Pilot Randomized TrialJungyoon Kim, Cheryl Beseler, Melissa Leypoldt, et al.
ACS Infectious Diseases|September 22, 2020
Antibacterial Activities of Ga(III) against <i>E. coli</i> Are Substantially Impacted by Fe(III) Uptake Systems and Multidrug Resistance in Combination with Oxygen LevelsChristopher J Neill, Susan Harris, Robert J Goldstone, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Journal of Clinical Hypertension (Greenwich, Conn.)|June 21, 2001
The Effects of Candesartan Cilexetil in Isolated Systolic Hypertension: A Clinical Experience TrialJoel M. Neutel, Matthew R. Weir, Marvin Moser, et al.
Journal of Drugs in Dermatology : JDD|July 30, 2020
Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/EthnicityNeal Bhatia, Jonathan S Weiss, Neil Sadick, et al.
Rural and Remote Health|December 7, 2023
Exploring barriers and promoters of CRC screening use among agricultural operators: a pilot study of an application of concept mappingCheryl Beseler, Jungyoon Kim, Roma Subramanian, et al.
Postgraduate Medicine|May 14, 2010
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesRobert Frederich, John H Alexander, Fred T Fiedorek, et al.
Journal of the American Academy of Dermatology|September 19, 2018
Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasisMark G Lebwohl, Jeffrey L Sugarman, Linda Stein Gold, et al.
American Journal of Medical Genetics. Part A|July 16, 2008
Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorderCatalina García-Nonell, Eugenia Rigau Ratera, Susan Harris, et al.
Cutis|March 21, 2019
Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studiesJeffrey L Sugarman, Jonathan S Weiss, Emil A Tanghetti, et al.
Journal of Pediatric Hematology/Oncology|September 10, 2002
CD3+CD4-CD8+NK- large granular lymphocytosis with neutropenia and evidence for clonality and T-cell receptor gene rearrangement: two pediatric casesMamidipudi T Krishna, Elizabeth Hodges, Frances L Lavender, et al.
Cancers|November 9, 2024
The Effect of a Tailored Educational Flyer on Colorectal Cancer Screening Among Rural Residents: Lessons Learned from a Pilot Randomized TrialJungyoon Kim, Cheryl Beseler, Melissa Leypoldt, et al.
ACS Infectious Diseases|September 22, 2020
Antibacterial Activities of Ga(III) against <i>E. coli</i> Are Substantially Impacted by Fe(III) Uptake Systems and Multidrug Resistance in Combination with Oxygen LevelsChristopher J Neill, Susan Harris, Robert J Goldstone, et al.
Pageof 6